小劑量多巴胺聯(lián)合多巴酚丁胺與氨溴索聯(lián)合人免疫球蛋白治療小兒重癥肺炎的療效

劉瑩

[摘要] 目的 探討在小兒重癥肺炎患兒中氨溴索+人免疫球蛋白與小劑量多巴胺+多巴酚丁胺治療的效果。 方法 此次方便抽選2017年2月—2019年2月期間該院醫(yī)治的64例小兒重癥肺炎患兒做研究，隨機(jī)分為對(duì)照組（32例）、研究組（32例）?；純壕Ｒ?guī)治療，對(duì)照組患兒加小劑量多巴胺+多巴酚丁胺治療，而研究組患兒加氨溴索+人免疫球蛋白治療，對(duì)比兩組的治療費(fèi)用、治療時(shí)間、體征改善時(shí)間、治療效果。 結(jié)果 研究組的治療費(fèi)用（1 520.12±135.84）元高于對(duì)照組（1 161.21±110.25）元，差異有統(tǒng)計(jì)學(xué)意義（t=11.604，P=0.000）。研究組的治療時(shí)間（6.61±1.12）d、肺部啰音消失時(shí)間（3.20±0.76）d、三凹征消失時(shí)間（2.61±0.91）d、心率改善時(shí)間（3.40±0.15）d、呼吸改善時(shí)間（2.20±0.17）d均短于對(duì)照組患兒[（8.13±1.84）d、（4.41±0.73）d、（3.54±1.02）d、（4.50±0.18）d、（3.25±0.14）d]，差異有統(tǒng)計(jì)學(xué)意義（t=3.992、6.495、3.849、26.557、26.971，P=0.000）。研究組的治療總有效率（93.75%）高于對(duì)照組（90.63%），但差異無(wú)統(tǒng)計(jì)學(xué)意義（χ2=0.217，P=0.641）。 結(jié)論 在小兒重癥肺炎患兒中，氨溴索+人免疫球蛋白與小劑量多巴胺+多巴酚丁胺治療的總有效率相近，其中，氨溴索+人免疫球蛋白的治療費(fèi)用高，但是該方法的治療時(shí)間短、患兒體征改善時(shí)間短。

[關(guān)鍵詞] 小兒重癥肺炎;氨溴索;人免疫球蛋白;多巴胺;多巴酚丁胺;療效

[中圖分類(lèi)號(hào)] R5 ? ? ? ? ?[文獻(xiàn)標(biāo)識(shí)碼] A ? ? ? ? ?[文章編號(hào)] 1674-0742（2019）06（c）-0115-03

[Abstract] Objective To investigate the effect of ambroxol + human immunoglobulin and low-dose dopamine + dobutamine in children with severe pneumonia. Methods Conveniently selected sixty-four children with severe pneumonia in our hospital who were treated in our hospital from February 2017 to February 2019 were randomly divided into the control group （32 cases） and the study group （32 cases）. All children were treated routinely. The control group received low-dose dopamine + dobutamine treatment， while the study group received ambroxol + human immunoglobulin treatment. The treatment cost， treatment time and physical signs recovery time， treatment effect of the two groups were improved. Results The treatment cost of the study group （1 520.12±135.84）yuan was higher than that of the control group （1 161.21±110.25） yuan， and the difference was significant（t=11.604， P=0.000）. The treatment time of the study group （6.61±1.12） d， the disappearance time of the lungs （3.20±0.76） d， the disappearance time of the three concave signs （2.61±0.91） d， the heart rate improvement time （3.40±0.15） d， the respiratory improvement time （2.20±0.17） d were shorter than those in the control group [（8.13±1.84） d， （4.41±0.73） d， （3.54±1.02） d， （4.50±0.18） d， （3.25±0.14） d]， the difference was statistically significant （t=3.992， 6.495， 3.849， 26.557， 26.971， P=0.000）. The total effective rate of treatment in the study group （93.75%） was higher than that in the control group （90.63%）， but the difference was not statistically significant （χ2=0.217， P=0.641）. Conclusion In children with severe pneumonia， the total effective rate of ambroxol + human immunoglobulin and low-dose dopamine + dobutamine is similar. Among them， ambroxol + human immunoglobulin is expensive. However， the method has a short treatment time and a short improvement in the physical signs of the child.